IFRX - InflaRx N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

InflaRx N.V.

Winzerlaer Strasse 2
Jena 07745
Germany
49 3641 508 180
http://www.inflarx.de

SectorHealthcare
IndustryBiotechnology
Full Time Employees36

Key Executives

NameTitlePayExercisedYear Born
Dr. Niels C. Riedemann M.D., Ph.D.Co-Founder, CEO & Exec. DirectorN/AN/A1972
Prof. Renfeng GuoCo-Founder, Chief Scientific Officer & Exec. DirectorN/AN/A1970
Mr. Arnd ChristChief Financial OfficerN/AN/A1966
Mr. Jason M. Marks J.D.Chief Legal Officer, Gen. Counsel & Corp. Sec.N/AN/A1976
Mr. Jordan SilversteinHead of Corp. Devel. & StrategyN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. It also develops IFX-2 for the treatment of chronic inflammation and autoimmune diseases. The company has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Corporate Governance

InflaRx N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.